[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Paxlovid, evidence base?", "description": "Paxlovid, it this an evidence based intervention in May 2022?\n\nPaper FDA EMU was based on\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2118542\n\nEPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients)\n\n1120 patients received nirmatrelvir plus ritonavir\n\n1126 received placebo\n\nRelative risk reduction\n\nRisk of progression to severe Covid-19, 89% lower than the risk with placebo\n\nAbsolute risk reduction\n\nhttps://www.precisionvaccinations.com/what-paxlovids-absolute-and-relative-covid-19-risk-reduction\n\n7% down to 1%\n\nsymptomatic, unvaccinated, non hospitalized adults\n\nat high risk for progression to severe coronavirus disease 2019\n\nJuly 16 and December 9, 2021\n\nIf vaccinated people and previously infected people are partly protected\n\nMore people would need to be treated to prevent one adverse event\n\nPfizer press release (5th November 2021)\n\nhttps://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate\n\nour oral antiviral candidate, \u2026 has the potential to save patients\u2019 lives, \n\nreduce the severity of COVID-19 infections, \n\nand eliminate up to nine out of ten hospitalizations\n\nPfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant\n\nhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment\n\nhttps://www.yalemedicine.org/news/12-things-to-know-paxlovid-covid-19\n\nhttps://www.fda.gov/media/155051/download\n\nThe results showed in all cases that nirmatrelvir was a potent inhibitor of its target.\n\nPAXLOVID\u2122 for Post-Exposure Prophylactic Use\n\nhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study\n\nEvaluated data from 2,957 adults\n\nPfizer observed risk reductions of 32% (5 day course)\n\n37% reduction (10 day course)\n\nThese results, however, were not statistically significant and, as such, the primary endpoint of reducing the risk of confirmed and symptomatic COVID-19 infection in adults who had been exposed to the virus through a household contact was not met.\n\n\n\n\n\nFACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS \nEMERGENCY USE AUTHORIZATION (EUA) OF PAXLOVID FOR CORONAVIRUS DISEASE 2019 (COVID-19) \n\nhttps://www.fda.gov/media/155051/download\n\nPAXLOVID is not an FDA-approved medicine in the United States. \n\nPAXLOVID is an investigational medicine \n\nSome medicines may interact with PAXLOVID and may cause serious side effects. \n\nIf you take too much PAXLOVID, call your healthcare provider or go to the nearest hospital emergency room right away. \n\nPossible side effects of PAXLOVID are:\n\nAllergic Reactions\n\ntrouble swallowing or breathing, swelling of the mouth, lips, or face, throat tightness, hoarseness, skin rash\n\nLiver Problems. Tell your healthcare provider right away, \n\nloss of appetite, yellowing of your skin and the whites of eyes (jaundice), dark-colored urine, pale colored stools and itchy skin, stomach area (abdominal) pain. \n\nOther possible side effects include: \naltered sense of taste, diarrhea, high blood pressure, muscle aches \n\nDr. Ashish K. Jha, White House, Covid-19 coordinator\n\nThe new White House Covid czar says avoiding all virus infections isn\u2019t the goal of U.S. pandemic policy.\n\nPaxlovid, push to reach the vulnerable\n\nDoctors are too hesitant to prescribe the drug\n\nhttps://en.wikipedia.org/wiki/Ashish_Jha\n\nSenior Advisor at Albright Stonebridge Group\n\nhttps://www.politico.com/newsletters/transition-playbook/2021/03/23/the-blob-abides-492214\n\nThe firm advises clients on international policy and global markets \n\nPatrick Vallance\n\nFrom 2012 to 2018, he was President of Research and Development at global pharmaceutical company, GlaxoSmithKline (GSK) \n\nhttps://www.telegraph.co.uk/news/2020/09/23/revealed-sir-patrick-vallance-has-600000-shareholding-firm-contracted/\n\nCashed \u00a35,000,000 GSK shares\n\nFuture jobs of FDA\u2019s haematology-oncology reviewers\n\nhttps://www.bmj.com/content/354/bmj.i5055.full\n\nhttps://www.npr.org/sections/health-shots/2016/09/28/495694559/a-look-at-how-the-revolving-door-spins-from-fda-to-industry?t=1651600609470\n\nMore than a quarter of the Food and Drug Administration employees\n\n(who approved cancer and hematology drugs from 2001 through 2010)\n\nleft the agency and now work or consult for pharmaceutical companies,", "link": "https://www.youtube.com/watch?v=iax-dL7F3qw", "date_published": "2022-05-04 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]